Clene (CLNN) Stock Analysis & AI Equity Report
Clene (CLNN) overview
Clene (CLNN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.2m and operating profit of USD -23.1m; the year-end share price was 5.87 USD and market capitalisation was USD 63.7m. Clene is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Clene's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Clene
Clene is a clinical-stage pharmaceutical company developing clean-surfaced nanotechnology therapeutics made from catalytic nanocrystals. Its platform is designed to support cellular metabolic and energy processes in diseased, stressed, or damaged cells. The company’s development efforts focus on central nervous system disorders, including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease, and include its lead candidate CNM-Au8, a gold nanocrystal suspension.
Generate the Clene report
Clene is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Clene and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Clene
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.